Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 64Neoplasms 38Venous Thromboembolism 29Leukemia 21Anemia, Refractory, with Excess of Blasts 20Myelodysplastic Syndromes 19Lymphoma 14Thrombocytopenia 13Multiple Myeloma 12Leukemia, Myelomonocytic, Chronic 12Venous Thrombosis 11Pulmonary Embolism 11Febrile Neutropenia 11Breast Neoplasms 10Myeloproliferative Disorders 9Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Neoplasms, Plasma Cell 8Lymphoma, Follicular 8Leukemia, Myeloid, Acute 8Primary Myelofibrosis 6Neutropenia 6Hodgkin Disease 6Hemophilia A 6Lung Neoplasms 5Anemia, Refractory 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precancerous Conditions 4Lymphoproliferative Disorders 4

Interventions

romiplostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Purpura, Thrombocytopenic × Classical hematology × Clear all
NCT01444417 2017-02-09

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Amgen

Phase 3 Completed
62 enrolled 16 charts 1 FDA
Classical hematology

Purpura, Thrombocytopenic, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡